Healthcare Industry News:  ExtraCorporeal Circulation 

Devices Ophthalmology Personnel

 News Release - April 19, 2006

Intelligent Medical Implants AG appoints Hillel Bachrach as Executive Chairman, and Hans-Jurgen Tiedtke as CEO of its subsidiary, IIP-Technologies GmbH

ZUG, Switzerland--(HSMN NewsFeed)--April 19, 2006--Intelligent Medical Implants AG ("IMI") (www.intmedimplants.com) announced today that it has appointed Hillel Bachrach as its new Executive Chairman. Mr. Bachrach has 30 years of hands-on management and directorship experience covering all aspects of the global commercial introduction of new, innovative and revolutionary medical technologies. He was previously President and CEO of Orex Computerized Radiography, which was sold to Eastman Kodak; President of Odin Medical Inc., which partnered with Medtronic; and the co-founder, Vice-Chairman and Director of ESC Medical Systems, Ltd., which went public in the U.S. and reached a value of nearly $1 billion in 1997/98. He is currently also Chairman of the Board of UltraSPECT Ltd. and NaviCath Ltd., both based in Haifa, Israel.

"I was extremely pleased to find such an advanced and sophisticated product as The Learning Retinal Implant System so close to market introduction," said Mr. Bachrach. "Once I had visited the company, I absolutely wanted to be part of this remarkable team."

IMI also announced that Hans-Jurgen Tiedtke has been appointed CEO of its subsidiary, IIP-Technologies (Bonn, Germany). In that role, Mr. Tiedtke will oversee IMI's Learning Retinal Implant System(TM) project. Mr. Tiedtke is an experienced medical device executive who has brought several products from the research and development stage to market introduction, including overseeing the regulatory and clinical trial processes. His successes include the introduction of a hydrodynamic thrombectomy catheter to both the European and U.S. markets; the development of innovative production equipment for suture material; and, the launch of a dynamic bubble trap for ExtraCorporeal Circulation, including European and U.S. regulatory approvals.

Recently, IIP-Technologies, on behalf of its parent IMI, announced that a limited clinical study related to its ongoing Early Human Trial has demonstrated that IMI's patented, first-generation Learning Retinal Implant(TM) enabled patients to see light--as well as simple patterns--via a wireless transmission of data and energy. This is the first time in the history of the development of artificial vision that completely wireless transmission of data and energy into an implant in the eye of long-time blind persons has resulted in pattern recognition.

About the Learning Retinal Implant System(TM)

IMI's Learning Retinal Implant System(TM) replaces the signal-processing functions of a healthy retina and provides input to the retinal nerve cells (the ganglion cells) that, in turn, provide input to the optic nerve and the brain. The System comprises three main components: (1) an implant, "The Retinal Stimulator", which is surgically placed into the eye of a patient, who wears (2) a pair of spectacles containing an integrated mini-camera and transmitter components for wireless signal and energy transmission ("The Visual Interface"). Via a cable, the spectacles are connected to (3) "The Pocket Processor" worn at the patient's waist. This device replaces the information processing function of the formally healthy retina. The use of a high-speed digital signal processor allows the provision of "intelligent information" to the implant (and the nerve cells) by using tuneable software to approximate the information processing normally carried out by the healthy retina. The entire process enables patients to optimize their visual perception during the learning phase. Indeed, using the patient's feedback on perception as an input for the tuning of The Pocket Processor is the unique, patent-protected feature of the System and constitutes the 'learning' capability of the Learning Retinal Implant System(TM).

About Intelligent Medical Implants ("IMI")

Intelligent Medical Implants AG, based in Zug, Switzerland--with its subsidiaries IIP-Technologies GmbH and Intelligent Medical Implants Ltd. (collectively referred to as "IMI Group")--is developing the Learning Retinal Implant System(TM), the first product of its developing neuro-prosthetics technology platform. The Company's platform aims to give blind people useful visual functionality. The technology integrated into the Company's first product will permit the development, marketing and licensing of further learning neural prostheses for active "intelligent" implantable medical devices. The primary shareholder of IMI is Polytechnos Venture Partners in Munich, Germany.

Safe-Harbor Statement

This press release may contain forward-looking statements, including 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Company. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.



Source: Intelligent Medical Implants

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.